Jeffrey M. Lynch
Research Subjects
Jeffrey M. Lynch has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
Bing Li
Novartis Institutes for Biomedical Research, United States
2 shared publicationsChuanxi Xiang
Novartis Institutes for Biomedical Research, United States
2 shared publicationsErik Meredith
Novartis Institutes for Biomedical Research, United States
2 shared publicationsGanesh Prasanna
Novartis Institutes for Biomedical Research, United States
2 shared publicationsParvaneh Katoli
Novartis Institutes of Biomedical Research
2 shared publicationsVeronica Saenz-Vash
Novartis Institutes for Biomedical Research, United States
2 shared publications
Latest Publications
- Open Access
- 1 December 2018
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 293 (52) , 20137-20156
Binding of a glaucoma-associated myocilin variant to the αB-crystallin chaperone impedes protein clearance in trabecular meshwork cells
- 1 December 2018
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 293 (52) , 20137-20156
Open AccessBinding of a glaucoma-associated myocilin variant to the αB-crystallin chaperone impedes protein clearance in trabecular meshwork cells
- Open Access
- 5 November 2018
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (11) , e0206801
Mutant myocilin impacts sarcomere ultrastructure in mouse gastrocnemius muscle
Myocilin (MYOC) is the gene with mutations most common in glaucoma. In the eye, MYOC is in trabecular meshwork, ciliary body, and retina. Other tissues with high MYOC transcript levels are skeletal muscle and heart. To date, the function of wild-type MYOC remains unknown and how mutant MYOC causes high intraocular pressure and glaucoma is ambiguous. By investigating mutant MYOC in a non-ocular tissue we hoped to obtain novel insight into mutant MYOC pathology. For this study, we utilized a transgenic mouse expressing human mutant MYOC Y437H protein and we examined its skeletal (gastrocnemius) muscle phenotype. Electron micrographs showed that sarcomeres in the skeletal muscle of mutant CMV-MYOC-Y437H mice had multiple M-bands. Western blots of soluble muscle lysates from transgenics indicated a decrease in two M-band proteins, myomesin 1 (MYOM1) and muscle creatine kinase (CKM). Immunoprecipitation identified CKM as a MYOC binding partner. Our results suggest that binding of mutant MYOC to CKM is changing sarcomere ultrastructure and this may adversely impact muscle function. We speculate that a person carrying the mutant MYOC mutation will likely have a glaucoma phenotype and may also have undiagnosed muscle ailments or vice versa, both of which will have to be monitored and treated.
- 5 November 2018
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (11) , e0206801
Open AccessMutant myocilin impacts sarcomere ultrastructure in mouse gastrocnemius muscle
Myocilin (MYOC) is the gene with mutations most common in glaucoma. In the eye, MYOC is in trabecular meshwork, ciliary body, and retina. Other tissues with high MYOC transcript levels are skeletal muscle and heart. To date, the function of wild-type MYOC remains unknown and how mutant MYOC causes high intraocular pressure and glaucoma is ambiguous. By investigating mutant MYOC in a non-ocular tissue we hoped to obtain novel insight into mutant MYOC pathology. For this study, we utilized a transgenic mouse expressing human mutant MYOC Y437H protein and we examined its skeletal (gastrocnemius) muscle phenotype. Electron micrographs showed that sarcomeres in the skeletal muscle of mutant CMV-MYOC-Y437H mice had multiple M-bands. Western blots of soluble muscle lysates from transgenics indicated a decrease in two M-band proteins, myomesin 1 (MYOM1) and muscle creatine kinase (CKM). Immunoprecipitation identified CKM as a MYOC binding partner. Our results suggest that binding of mutant MYOC to CKM is changing sarcomere ultrastructure and this may adversely impact muscle function. We speculate that a person carrying the mutant MYOC mutation will likely have a glaucoma phenotype and may also have undiagnosed muscle ailments or vice versa, both of which will have to be monitored and treated.
- 1 July 2018
- Published by Elsevier in Protein Expression and Purification
- Vol. 147, 38-48
Full-length myocilin protein is purified from mammalian cells as a dimer
- 1 July 2018
- Published by Elsevier in Protein Expression and Purification
- Vol. 147, 38-48
Full-length myocilin protein is purified from mammalian cells as a dimer
- 28 February 2008
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 47 (12) , 3697-3704
Regulation of the Calreticulin Gene by GATA6 and Evi-1 Transcription Factors
Calreticulin is a Ca2+-buffering chaperone of the endoplasmic reticulum. The protein is highly expressed in embryonic heart but downregulated in postnatal heart, indicating that expression of calreticulin in the heart is highly regulated. In this study we identify GATA6 and Evi-1 transcription factors as new regulators of the calreticulin gene. In neonatal rat ventricular cardiomyocytes and mouse fibroblasts the calreticulin gene is activated by GATA6 but repressed by Evi-1. Furthermore, transactivation of the calreticulin gene by GATA6 is suppressed by Evi-1, suggesting an antagonistic role between both GATA6 and Evi-1. Using EMSA, ChIP analysis, and site-specific mutagenesis, we showed that GATA6 and Evi-1 bind to site 1 on the calreticulin promoter. GATA6 and Evi-1 are highly expressed early during cardiogenesis of ES cells, suggesting that they may regulate expression of the calreticulin gene during cardiac development.
- 28 February 2008
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 47 (12) , 3697-3704
Regulation of the Calreticulin Gene by GATA6 and Evi-1 Transcription Factors
Calreticulin is a Ca2+-buffering chaperone of the endoplasmic reticulum. The protein is highly expressed in embryonic heart but downregulated in postnatal heart, indicating that expression of calreticulin in the heart is highly regulated. In this study we identify GATA6 and Evi-1 transcription factors as new regulators of the calreticulin gene. In neonatal rat ventricular cardiomyocytes and mouse fibroblasts the calreticulin gene is activated by GATA6 but repressed by Evi-1. Furthermore, transactivation of the calreticulin gene by GATA6 is suppressed by Evi-1, suggesting an antagonistic role between both GATA6 and Evi-1. Using EMSA, ChIP analysis, and site-specific mutagenesis, we showed that GATA6 and Evi-1 bind to site 1 on the calreticulin promoter. GATA6 and Evi-1 are highly expressed early during cardiogenesis of ES cells, suggesting that they may regulate expression of the calreticulin gene during cardiac development.